t - ICON plc

Keynote speakersQuentin Peel, Associate Editor, The Financial TimesFew people understand the dramas unfolding on the international stage better than QuentinPeel. He excels at relating politics and economics, with a bit of history and geography, toexplain the tensions at work in the world. Quentin has special depth on issues related to theevolution of the EU. He has been very well received as an analyst of the current economiccrisis. He also has focused on failed and failing states and countries in transition (fromdictatorship to democ racy, from poverty to prosperity). Having covered major world-changing events over thepast 30 years as an eye-witness reporter, he sees the social, political and economic forces shaping world affairswith historical perspective, personal knowledge and deep insight.Stephen Carver, Project Management Specialist and Lecturer,Cranfield University, One of Europe's top business schoolsStephen is rated as one of the top 3 lecturers at Europe’s top MBA Business Schools - Cranfield.He has a reputation of taking complex management concepts and being able to distil themdown, into highly informative and fun lectures - often using “storytelling” techniques. Hisattitude is “if you haven’t done it – you shouldn’t be teaching it!” Unusually, for an academic,he has actually has spent most of his working life in real business and still runs his own, highly successful,Project Management Company (his client list now reads like the FTSE/Dow top 100!). Stephen is an unusualblend of Academic, Businessman and Teller of Tales. He has taught in UK, US Holland, Germany, France,Portugal, Singapore, Hong Kong and Australia and has appeared on National Radio and TV. Stephen hasundertaken Project Management and Public Speaking assignments for many clients in the UK, Europe, theMiddle & Far East including: Goldman Sachs, BP, Morgan Stanley, Imperial, Linklaters, Merrill Lynch,Threadneedle, Sodexho, MOD, BAE.Charles Sabine, Emmy-award winning NBC Journalist, War Correspondent, and Huntington'sDisease patientCharles Sabine has worked for the US Network NBC for 26 years. That career took him, via 12wars, six revolutions and four earthquakes, to most of the news events of Europe, The MiddleEast, Africa and Asia. He learnt first hand the extraordinary limits that the human spirit iscapable of reaching, in the face of tragedy inflicted by both nature and mankind. In 2008, hedecided to put the lessons of those experiences to a different use, when he became a pioneering spokesman forfreedom of scientific research, Dementia, and, in particular, Huntington’s Disease, which has ravaged his family.Alan Crane CBE, Vice President, Chartered Institute of Building, and former ChiefExecutive Officer, Bovis International, Travers Morgan Consulting Group and Christiani& Nielsen GroupAlan has spent 40 years in the Construction Industry, including Chief Executive appointmentswith Bovis International, Travers Morgan Consulting Group and Christiani & Nielsen Group.He has had responsibility for a wide range of major projects including the Development &Construction of Canary Wharf in London, and Eurodisney. He has extensive international experience, throughoutEurope, Middle and Far East, Asia and Australia. He was a member of the Strategic Forum of the ConstructionIndustry, Chairman of the Institution of Civil Engineers Management Board, member of the ArchitectsRegistration Board and of a number of Government Task Forces, and currently Chair of CIOB Learning &Professional Practice Board. He provides consulting advice on Business Performance Improvement, Partnering,Supply Chain management and Value Management. He is the author of a number of industry and Task Forcereports and “How To” guidance documents. He established and chaired the group responsible for development ofthe UK industry Key Performance Indicators and Benchmark system. Following the issue of Sir John Egan's TaskForce Report ''Rethinking Construction'' in late 1998 he was asked by Government and Industry to establish andChair the Movement for Innovation (M4i) with the task of motivating industry to radically change the way inwhich it operates, and to adopt the recommendations and targets of the Egan report . In April 2002 he becameChairman of Rethinking Construction. With the merger of Rethinking Construction and the Construction BestPractice Programme he became a Director of the combined organisation, Constructing ExcellenceDalvir Gill, President, Late Stage Development, PharmaNetDr. Dalvir Gill is President of Late Stage Development for Pharmanet, a global, drugdevelopment services company, that provides a comprehensive range of services to thepharmaceutical, biotechnology, generic drug, and medical device industries. He has more than20 years of experience in international clinical research and in his current position; he hasoverall responsibility for all PharmaNet Phase ll to lV services. Prior to PharmaNet, Dr. Gillspent 9 years in various leadership roles at Rhone-Poulenc Rorer (RPR, now Sanofi Aventis) in the United Statesand Europe. During his tenure at RPR, he played a key role in the submission of a number of successfulregulatory filings and also held positions in Process Improvement, Health Economics and Corporate Marketing.Dr. Gill earned his Ph.D in Pathobiology from the Faculty of Medicine of the Royal Free Hospital School ofMedicine and has authored numerous peer reviewed publications in the fields of vascular diseases and diabetes.Dr Gill is also an elected fellow of the Royal Society of Medicine.Dr Rabinder Buttar, President and CEO, ClinTec International GroupDr. Rabinder Buttar is the Founder, President and CEO of ClinTec International, a globalclinical research organization established in 1997 and present in over 40 countries worldwide.Included in Real Business’ List of Britain’s 100 Most Entrepreneurial Women, Dr Buttar is therecipient of several business awards including the Lloyds TSB Business and CommercialExcellence Jewel Award. With two doctorate degrees and management qualifications fromBritish Universities, Dr Buttar has spent 20 years within the pharmaceutical and CRO industry in leadingcompanies such as GSK, Astellas and Wyeth. Under Dr Buttar's leadership ClinTec has grown from inceptionto a global organization with a strong presence in all major and emerging markets including the Middle East andAfrica. The company now provides innovative clinical research services to 11 of the top 25 pharmaceuticalcompanies in the world and has established its Global Academy of Clinical Research Excellence (ACRE).Dr Buttar served previously on the Board of the Institute of Clinical Research and currently serves on theEditorial Board of Scrip Clinical Research and Journal of Clinical Studies. She is a Fellow of the Royal Societyof Medicine, and Regional Director of the Year (Glasgow & West of Scotland) at Institute of Directors, UK.The Scottish Parliament has congratulated Dr Buttar and ClinTec for their contribution to life sciences andprovision of clinical research teams across the globe.Harris Koffer, Pharm.D, President and Chief Operating Officer,ReSearch Pharmaceutical Services (RPS)Dr. Harris Koffer is President and Chief Operating Officer for Research PharmaceuticalServices (RPS), a clinical research organization providing services to the Pharmaceutical andBiotechnology industries in support of clinical drug development. Prior to joining RPS, Dr.Koffer served as Vice President, Clinical Trials and Pharmaceutical Business Development, forQuest Diagnostics; Vice President and General Manager of Covance Clinical Services and President of CovancePeriapproval Services. In these roles, he was responsible for global central laboratory services as well as fullservice clinical research and development capabilities for Phases 1 through 4 of drug development. In additionto over 28 years of experience in clinical drug development, he has served as Adjunct Assistant Professor ofPharmacy in Medicine at the University of Pennsylvania School of Medicine and Clinical Associate Professorof Pharmacy at the Philadelphia College of Pharmacy and Science. Dr. Koffer has published and presentednumerous papers in the fields of cardiovascular clinical pharmacology and pharmacoeconomics. He earned botha BS in Pharmacy and a Doctor of Pharmacy degree from the Philadelphia College of Pharmacy and Scienceand completed a Fellowship in Clinical Pharmacology at Thomas Jefferson University Hospital in Philadelphia.Sebastian Pacios, Senior Vice President, Clinical Development, Europe, Middle East andAfrica, PPD, Inc.Sebastian Pacios joined PPD in January 2008 as senior vice president for clinical developmentof Europe, Middle East and Africa. He leads Phase II-IV operations in the well-establishedclinical research markets of Western and Central Europe, as well as some of our newest officesin developing regions for clinical research, such as Turkey, Russia and the Ukraine. Paciosprovides strategic direction to ensure delivery of international and global clinical research projects andcoordination of operational processes across all PPD offices in the region. Pacios brings extensive globaldevelopment experience, first as a co-founder of a regional contract research organization and then through anumber of senior management roles with a global CRO where he most recently served as vice presidentresponsible for clinical operations and project management in Europe, Africa and Asia-Pacific. He has taughtclinical trial management courses in Spain for a number of years at the University of Pamplona, the Universityof Barcelona, the University of Alcala de Henares and the University of Valencia, and is affiliated with theAssociation of Clinical Research Professionals. Pacios holds a medical degree from the Universidad Autónomade Madrid and is a licensed practical physician at the Colegio de Medicos de MadridAndy Parrett, PCMG Chairman and European Outsourcing Manager,MedImmune - AstraZeneca’s worldwide biologics business unitAndy manages the European clinical development outsourcing work for MedImmune;AstraZeneca’s worldwide biologics business unit. He has a degree in genetics and abackground in clinical science and medical research gained as an embryologist at Bourn HallClinic and a neuroscientist at The Royal London Hospital. Andy has been with MedImmunesince March 2009 and prior to that spent 6 years building the outsourcing team at Mundipharma and 4 yearsworking in contracts, proposals and project finance teams at various CROs – most notably MDS, PRA andParexel. In addition, Andy has been an active committee member of the PCMG since early 2004 and Chairmansince January 2009. Andy is an enthusiastic innovator around the application of project managementmethodologies within clinical development outsourcing teams and in recent years has published and presentedcontributions on relational contracting models, scope management systems, stakeholder analysis benefits andrelationship management strategies. More recently Andy’s external interests have returned to his first love –genetics – and the application of evolutionary psychology to models in organisational behaviour.Warren Myers, Formerly Head of R&D Strategic Sourcing, AmgenWarren Myers is a 25-year veteran of the biopharmaceutical industry whose backgroundincludes experience both as a scientist and R&D procurement leader. Following completion ofa bachelor’s degree in biology from the University of California, Santa Barbara in 1984, Warrenserved as a scientist in the biotechnology industry and academia. Warren’s research focused onapplications of cellular and molecular biology to the treatment of cancer. Warren joinedBayer’s biotechnology division in 1991 focusing his career on improving drug development efficiency. Whilecompleting a Master’s degree in Technology Management from Pepperdine University, Warren studied crossindustryoutsourcing best practices as applied to the biopharmaceutical industry. This research enabled Warrento lead the establishment of Bayer’s drug development outsourcing capability. Warren left Bayer to help Amgenestablish it’s strategic sourcing organization. During his ten years at Amgen, Warren held positions of increasingresponsibility culminating in the role of Global Head, Strategic Sourcing and Procurement for Research andDevelopment. Warren is noted for his contributions to the advancement of strategic sourcing and supplierrelationship management practices within the biopharmaceutical industry.Vasco M. Grilo, Vice-President Global Pharmaceutical R&D Sourcing (GPS),Johnson & Johnson Pharmaceutical Research & Development, L. L. C.Vasco has an Engineering degree in Metallurgy and Material Sciences from the TechnicalUniversity of Lisbon, Portugal. He subsequently received his MBA from SDA Bocconi in Milanand a Masters in Manufacturing Systems Engineering from Lehigh University in the US. Hestarted his career with Carrier Corporation in operations and has held assignments in the US,Europe and Latin America. Vasco joined Johnson & Johnson Consumer EMEA procurement organization in2003. In 2006 moved to Janssen-Cilag as Procurement Director for J&J's Southern European commercialcompanies. Vasco has served as Senior Director Non-Clinical within Global Pharmaceutical R&D Sourcing.Since March 1, 2009 he has been appointed as Vice President, Global Pharmaceutical R&D Sourcing.Matthias R. Evers, Principal, McKinsey & CompanyMatthias Evers is a Principal from the Hamburg Office in Germany. Matthias joined McKinsey& Company in April 2002. He has worked globally in the pharmaceutical industry, servingoriginators as well as generic players. His main interests are in the areas of R&D with specificfocus on the interface between development and commercial and strategy. Recent examples ofhis work are: • Transforming Development holistically for a top-10 originator to build excellencewith focus on overarching success drivers (e.g., team leadership models) as well as functional excellence invarious areas (e.g., Clinical Development / Operations, Regulatory, Biologics and CMC) • Supporting an EUbiotech player to define a sustainable business model and long-term strategy • Defining the R&D and M&Astrategy for a mid-sized pharmaceutical player • Building new R&D, Medical Affairs, and Pharmacovigilanceorganizations (strategy, structure, processes, people) in a European post-merger situation • Assessing investmentscenarios and planning implementation of mammalian cell culture manufacturing capacity expansion for a top-10 originator • Redefining entire R&D strategy and operating model (Research, Development, Regulatory) of amid-sized originator • Crafting a Medical Marketing strategy with implications on processes and organizationaldesign of country organizations for a major pharmaceutical player • Crafting an Research informatics strategy fora global pharma client • Launch preparation for two upcoming Primary Care Drugs across the European top-5markets for a global pharmaceutical player. Matthias, having a background as a biochemist, holds a Ph.D. inChemistry/Biochemistry from the University of Bochum. Before his career with McKinsey, he worked as aResearch Associate and Postdoctorate at a center for molecular neurobiology in Hamburg and authored severalarticles in the field of bioinformatics and molecular biology.Gareth Down Ph.D., Head of European Healthcare, William Blair InternationalGareth Down, Ph.D., vice president, joined William Blair International in 2000. Since joiningWilliam Blair International, he has worked on a variety of public and private merger-andacquisitiontransactions and is focused on the health care sector. Mr. Down has a B.S. in cellularand molecular biology from University College London and a Ph.D. in clinical biochemistryfrom Cambridge University.Jane Clarke, Formerly Assistant Vice President, Clinical Development Support, PfizerJane has over 20 years Clinical Research experience having worked for a number of US basedmulti-national Pharma companies. Fluent in French and Italian she initially worked as a CRA inthese countries before undertaking broader Clinical Programme Management responsibilities,allowing her to focus her interests in Clinical Process Design and Optimization. With the adventof ‘e’ Clinical Trials, Jane immediately recognized the potential benefits of these tools torecognize a step change in operational excellence and cost effectiveness in Clinical Research. She developed anew capability within Wyeth Research – an organization dedicated to the development, implementation andsupport of highly integrated IT systems designed for Clinical Research: CTMS, EDC, IVR, ePRO, TMF etc Usingthis group, Jane led a successful implementation of EDC at Wyeth, moving the organization from 9% to 90%uptake in 11 months and subsequently transitioned the organization from a custom built to commercial EDCsolution, enabling adaptive trial design and ePRO capabilities.Stefania Sordoni, Global Procurement Country Lead, EMEA, MSDDr Stefania Sordoni holds a Degree in Economics from the University La Sapienza, Rome. She complete herdissertation in Prices and Reimbursability of Drugs in the European Community and was further certified fromthe Bocconi University in Milan in Contract Management. She has served in positions of increasing responsibilityin Procurement, Site Services and Contract, Management for IRBM Site, a Basi Research site fully owned byMerck & Co. with a great focus on scientific outsourcing, in strong collaboration and partnership with the UScollegues. She was named in 2007 EMEA Lead for Research Prourement, being a key interface with senior Merckstakeholders in EMEA. She worked closely with Global Procurement colleagues to develop relationships and addvalue to major global and regional Merck Research Laboratories activities, as well as leading and co-ordinatingall EMEA activities within Research Procurement categories of spend. She launched in EMEA a full outsourcingof clinical trials. She is member of many Procurement and Scientific AssociationPre & Post-conference workshopsPre-conference workshop WTuesday 16th November 2010, 13:00 - 17:00PERFORMANCE MANAGEMENT: TOOLS FORMEASURING THE PERFORMANCE OF SERVICEPROVIDERS AND SPONSORSWorkshop leader: Roger Joby, Director, 1to1to1.Pre-conference workshop XTuesday 16th November 2010, 13:00 - 17:00FOCUS ON NEW REGULATORY EXPECTATIONSFOR VENDOR OVERSIGHTWorkshop leader: Jane Winter, Director,Pharma Business Solutions LtdPost-conference workshop YFriday 19th November, 9:00 - 13:00MANAGING THE PROJECT AND CONTRACTMANAGEMENT CHALLENGES OF WORKING WITHFUNCTIONAL SERVICE PROVIDERSWorkshop leader: Gary Aldam, Director Life Sciences,Harpum Consulting Limited.Post-conference workshop ZFriday 19th November, 9:00 - 13:00HONING YOUR CRO COST AND CONTRACTNEGOTIATION SKILLSWorkshop leader: Richard Barrett,Contract & Outsourcing Services Ltd.t: +44 (0) 20 7017 7481 f: +44 (0) 20 7017 7823 w: www.ct-partnerships.com